Symphony Therapeutics Debuts Novel Nanotech Solution for Dry Eye Relief
Raleigh, Sunday, 8 March 2026.
This Wednesday, Symphony Therapeutics unveils a 200-micron wafer that transforms into a tissue-interlocking hydrogel, offering a patented, novel approach to treating dry eye symptoms globally.
Unveiling the NanoM-Wafer™
Symphony Therapeutics, LLC, a subsidiary of Integral BioSystems established in 2023, is set to present pivotal data regarding its proprietary ocular insert technology this week [1]. The disclosure is scheduled for 9 AM ET on Wednesday, March 11, 2026, at the Raleigh Convention Center in North Carolina [1]. This presentation will take place in Marriott University C as part of the 29th Annual TechConnect World Innovation Conference and Expo, marking a significant step in the company’s public disclosure of its research and development efforts [1].
Technical Specifications and Mechanism
The focal point of the presentation is the NanoM-Wafer™ Artificial Tear Film Ocular Insert, a medical device designed to alleviate dry eye symptoms [1]. Physically, the device is a 200-micron dry wafer intended for placement under the lower eyelid [1]. Upon contact with the ocular environment, the wafer hydrates and transforms into a transparent hydrogel [1]. This hydrogel is engineered to interlock with the underlying tissue before eventually dissolving on the ocular surface [1]. The wafer’s composition is a precise mixture of lipids, polymers, and a hydration-enhancing excipient specifically formulated to produce tear mucin [1].
Clinical Implications and Strategic Outlook
Shikha P. Barman, PhD, has indicated that the device’s ability to interlock with tissue enhances its residence time on the eye, a factor that could translate into long-term relief for patients [1]. To ensure safety and tolerability, prototypes of the NanoM-Wafer™ have already undergone testing in rabbit eye models [1]. Commercially, Symphony Therapeutics plans to introduce the device initially in the European market [1]. The technology, alongside the company’s OcuHeal™ platform, has secured patent protection in 14 global jurisdictions, including the United States, Canada, Europe, India, China, and Japan [1]. Following the presentation, the company intends to initiate investor outreach in the coming months to secure partners for the further development of these delivery platforms [1].